Aug. 24, 2011
GREENFORD, UK—Glaxo Group Limited (GSK) will take a £1,250,000 (about $2 million) equity stake in Autifony Therapeutics Ltd., a new British biotech company spun off from GSK. Under the agreement, announced on August 22, the British subsidiary of the global pharmaceutical giant GlaxoSmithKline, will own 25.4% of Autifony. In exchange, the Glaxo Group will hand over voltage-gated ion channel modulator